KR20060006785A - 인산염 유도체 - Google Patents
인산염 유도체 Download PDFInfo
- Publication number
- KR20060006785A KR20060006785A KR1020057018283A KR20057018283A KR20060006785A KR 20060006785 A KR20060006785 A KR 20060006785A KR 1020057018283 A KR1020057018283 A KR 1020057018283A KR 20057018283 A KR20057018283 A KR 20057018283A KR 20060006785 A KR20060006785 A KR 20060006785A
- Authority
- KR
- South Korea
- Prior art keywords
- propofol
- derivative
- hydroxy compound
- phenolic hydroxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title claims abstract description 9
- -1 phenolic hydroxy compound Chemical class 0.000 claims abstract description 50
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 150000002373 hemiacetals Chemical class 0.000 claims abstract description 11
- 125000003172 aldehyde group Chemical group 0.000 claims abstract description 8
- 230000000865 phosphorylative effect Effects 0.000 claims abstract description 8
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 44
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 38
- 229960004134 propofol Drugs 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 20
- 239000008139 complexing agent Substances 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 239000003093 cationic surfactant Substances 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004355 nitrogen functional group Chemical group 0.000 claims description 6
- 230000003444 anaesthetic effect Effects 0.000 claims description 5
- KWANHQRNGHCFDR-UHFFFAOYSA-L disodium 3-[(3-dodecoxy-3-oxopropyl)amino]propanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CCNCCC([O-])=O.CCCCCCCCCCCCOC(=O)CCNCCC([O-])=O KWANHQRNGHCFDR-UHFFFAOYSA-L 0.000 claims description 5
- 150000002440 hydroxy compounds Chemical class 0.000 claims description 5
- CUYHNKTTWOHAMC-UHFFFAOYSA-N 2,2,3-trihydroxypentanedial Chemical compound O=CCC(O)C(O)(O)C=O CUYHNKTTWOHAMC-UHFFFAOYSA-N 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002563 ionic surfactant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- BJHATUDJCAXTIH-UHFFFAOYSA-N [2,6-di(propan-2-yl)phenyl] dihydrogen phosphate Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OP(O)(O)=O BJHATUDJCAXTIH-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XYYUAOIALFMRGY-UHFFFAOYSA-N 3-[2-carboxyethyl(dodecyl)amino]propanoic acid Chemical compound CCCCCCCCCCCCN(CCC(O)=O)CCC(O)=O XYYUAOIALFMRGY-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 1
- DZRPKVSVFCSUIT-UHFFFAOYSA-N [6-[2,6-di(propan-2-yl)phenoxy]oxan-2-yl] dihydrogen phosphate Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OC1OC(OP(O)(O)=O)CCC1 DZRPKVSVFCSUIT-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005332 alkyl sulfoxy group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901815 | 2003-04-15 | ||
| AU2003901815A AU2003901815A0 (en) | 2003-04-15 | 2003-04-15 | Phosphate derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060006785A true KR20060006785A (ko) | 2006-01-19 |
Family
ID=31500852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057018283A Withdrawn KR20060006785A (ko) | 2003-04-15 | 2004-04-14 | 인산염 유도체 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070135390A1 (https=) |
| EP (1) | EP1615935A4 (https=) |
| JP (1) | JP2006523622A (https=) |
| KR (1) | KR20060006785A (https=) |
| CN (1) | CN1774442A (https=) |
| AU (1) | AU2003901815A0 (https=) |
| BR (1) | BRPI0409552A (https=) |
| CA (1) | CA2521837A1 (https=) |
| MX (1) | MXPA05010509A (https=) |
| WO (1) | WO2004092187A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60140141D1 (de) * | 2000-11-14 | 2009-11-19 | Vital Health Sciences Pty Ltd | Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten |
| AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| BR0211673A (pt) * | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons |
| ATE487456T1 (de) * | 2001-12-13 | 2010-11-15 | Vital Health Sciences Pty Ltd | Transdermaler transport von verbindungen |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| EP1589964B1 (en) * | 2003-01-17 | 2011-11-23 | Vital Health Sciences Pty Ltd. | Compounds having anti-proliferative properties |
| JP4847437B2 (ja) * | 2004-03-03 | 2011-12-28 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | アルカロイド製剤 |
| BRPI0513673B8 (pt) * | 2004-08-03 | 2021-07-27 | Vital Health Sciences Pty Ltd | método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica |
| WO2006092024A1 (en) * | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
| US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| WO2007070981A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd | Compounds having cytokine modulating properties |
| CN101715437B (zh) | 2007-05-09 | 2013-06-12 | 特色疗法股份有限公司 | 立体异构异丙酚治疗性化合物 |
| MY147215A (en) | 2007-05-09 | 2012-11-14 | Pharmacofore Inc | Therapeutic compunds |
| US20090198145A1 (en) * | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| EP2531047B1 (en) | 2010-02-05 | 2024-11-13 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| ES2829386T3 (es) | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| MX383940B (es) | 2015-12-09 | 2025-03-14 | Phosphagenics Ltd | Formulación farmacéutica que contiene tocol fosfato. |
| IL267006B2 (en) * | 2016-12-21 | 2024-11-01 | Phosphagenics Ltd | Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof |
| US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
| US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
| US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
| US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
| WO2022155656A1 (en) | 2021-01-13 | 2022-07-21 | Rodan & Fields, Llc | Cosmetic compositions |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2407823A (en) * | 1946-09-17 | Antihemorrhagic esters and methods | ||
| US2667479A (en) * | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
| US2913477A (en) * | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
| US3212901A (en) * | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
| DE2526938C2 (de) * | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitaminpräparate |
| US4141938A (en) * | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
| US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
| US4299906A (en) * | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| IT1157269B (it) * | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| JPS6191137A (ja) * | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
| JPH0667968B2 (ja) * | 1985-11-12 | 1994-08-31 | 東亞合成化学工業株式会社 | 乳化重合体の製造方法 |
| DE3702766A1 (de) * | 1987-01-30 | 1988-08-11 | Henkel Kgaa | Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern |
| JP3070744B2 (ja) * | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | ベクトル処理装置 |
| US4952495A (en) * | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2645741B1 (fr) * | 1989-03-20 | 1995-06-23 | Dior Christian Parfums | Procede pour fixer un produit sur la membrane d'un keratinocyte au moyen d'une liaison ligand-recepteur, procede de preparation d'un tel produit, produit obtenu, composition cosmetique ou pharmaceutique le contenant et son procede de preparation |
| US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
| US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
| DE3927113C2 (de) * | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
| IT1236843B (it) * | 1989-11-22 | 1993-04-21 | Simes | Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati |
| US5374645A (en) * | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
| FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5114957A (en) * | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
| SE9003665D0 (sv) * | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | Morphine prodrugs |
| US5643597A (en) * | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
| FR2679904A1 (fr) * | 1991-08-01 | 1993-02-05 | Lvmh Rech | Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues. |
| US5474891A (en) * | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
| SG48108A1 (en) * | 1991-11-22 | 1998-04-17 | Lipogenenics Inc | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5282312A (en) * | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
| US5741518A (en) * | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| US6384043B1 (en) * | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| TW252918B (https=) * | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
| WO1995014457A1 (en) * | 1993-11-27 | 1995-06-01 | Knoll Ag | Compositions comprising iminium ion scavengers and/or nitrite scavengers |
| FR2715565B1 (fr) * | 1994-01-31 | 1996-03-15 | Oreal | Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation. |
| US5554781A (en) * | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
| US5589504A (en) * | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| FR2730928B1 (fr) * | 1995-02-23 | 1997-04-04 | Oreal | Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique |
| US5607968A (en) * | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
| WO1997014705A1 (fr) * | 1995-10-17 | 1997-04-24 | Showa Denko K.K. | Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants |
| FR2741263B1 (fr) * | 1995-11-22 | 1997-12-26 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique |
| US5885595A (en) * | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
| CA2209690A1 (en) * | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
| AUPO309896A0 (en) * | 1996-10-18 | 1996-11-14 | Australian National University, The | Novel phosphosugars and phosphosugar-containing compounds having anti-inflammatory activity |
| US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
| US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
| IL131651A0 (en) * | 1997-03-13 | 2001-01-28 | Hexal Ag | A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same |
| US7179486B1 (en) * | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| FR2764891B1 (fr) * | 1997-06-04 | 2001-04-13 | Pacific Corp | Derive de l'acide l-ascorbique stable dans l'eau, procede pour sa preparation et composition cosmetique de blanchiment de la peau le contenant |
| US5928631A (en) * | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5776915A (en) * | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
| US6096326A (en) * | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
| US6254853B1 (en) * | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| AU4972599A (en) * | 1998-07-07 | 2000-01-24 | Transdermal Technologies, Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
| US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| US6770672B1 (en) * | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| DK1115398T3 (da) * | 1998-09-23 | 2010-08-16 | Res Dev Foundation | Tocopheroler, tocotrienoler, andre chroman- og sidekædederivater og anvendelser deraf |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| AUPQ037499A0 (en) * | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
| AUPP829399A0 (en) * | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
| US6156354A (en) * | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
| US6184247B1 (en) * | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
| US6641847B1 (en) * | 1999-06-01 | 2003-11-04 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
| WO2001015593A2 (en) * | 1999-09-02 | 2001-03-08 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
| WO2001022937A1 (en) * | 1999-09-27 | 2001-04-05 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
| RU2263672C2 (ru) * | 2000-02-11 | 2005-11-10 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение |
| US20030035812A1 (en) * | 2000-02-29 | 2003-02-20 | Shinobu Ito | Immune enhancement compositions and use thereof |
| US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
| US6444220B2 (en) * | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
| US6362234B1 (en) * | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
| JP4818500B2 (ja) * | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | トコトリエノール誘導体及びその製造方法 |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| DE60140141D1 (de) * | 2000-11-14 | 2009-11-19 | Vital Health Sciences Pty Ltd | Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten |
| US20020151467A1 (en) * | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
| US20020131994A1 (en) * | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
| US6849271B2 (en) * | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
| BR0211673A (pt) * | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| AU2002951045A0 (en) * | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
| ATE487456T1 (de) * | 2001-12-13 | 2010-11-15 | Vital Health Sciences Pty Ltd | Transdermaler transport von verbindungen |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| US20040067890A1 (en) * | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
| EP1589964B1 (en) * | 2003-01-17 | 2011-11-23 | Vital Health Sciences Pty Ltd. | Compounds having anti-proliferative properties |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
| AU2003901813A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
| JP4847437B2 (ja) * | 2004-03-03 | 2011-12-28 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | アルカロイド製剤 |
| BRPI0513673B8 (pt) * | 2004-08-03 | 2021-07-27 | Vital Health Sciences Pty Ltd | método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica |
| US9168216B2 (en) * | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| WO2007070981A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd | Compounds having cytokine modulating properties |
-
2003
- 2003-04-15 AU AU2003901815A patent/AU2003901815A0/en not_active Abandoned
-
2004
- 2004-04-14 EP EP04727178A patent/EP1615935A4/en not_active Withdrawn
- 2004-04-14 JP JP2006504008A patent/JP2006523622A/ja active Pending
- 2004-04-14 BR BRPI0409552-9A patent/BRPI0409552A/pt not_active IP Right Cessation
- 2004-04-14 CN CNA2004800099280A patent/CN1774442A/zh active Pending
- 2004-04-14 MX MXPA05010509A patent/MXPA05010509A/es unknown
- 2004-04-14 US US10/551,200 patent/US20070135390A1/en not_active Abandoned
- 2004-04-14 CA CA002521837A patent/CA2521837A1/en not_active Abandoned
- 2004-04-14 WO PCT/AU2004/000491 patent/WO2004092187A1/en not_active Ceased
- 2004-04-14 KR KR1020057018283A patent/KR20060006785A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1615935A1 (en) | 2006-01-18 |
| JP2006523622A (ja) | 2006-10-19 |
| CA2521837A1 (en) | 2004-10-28 |
| EP1615935A4 (en) | 2008-04-23 |
| US20070135390A1 (en) | 2007-06-14 |
| WO2004092187A1 (en) | 2004-10-28 |
| CN1774442A (zh) | 2006-05-17 |
| AU2003901815A0 (en) | 2003-05-01 |
| BRPI0409552A (pt) | 2006-04-18 |
| MXPA05010509A (es) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060006785A (ko) | 인산염 유도체 | |
| CN1064365C (zh) | 混合胶束 | |
| US4320121A (en) | Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds | |
| JPH047353B2 (https=) | ||
| JPS5849393A (ja) | 合成りん脂質化合物とその製造方法 | |
| KR101695836B1 (ko) | 경피흡수용 고분자-리포좀 나노복합체 조성물 및 그 제조방법 | |
| JP3218313B2 (ja) | エルシル−、ブラシジル−およびネルボニル誘導体、その製造方法、それを含有する腫瘍および原虫によるおよび菌類による疾患に対抗するための医薬および自己免疫疾患および骨髄障害の治療のための医薬およびその医薬の製造方法 | |
| CN100584851C (zh) | 仲醇磷酸盐 | |
| EP1241172B1 (en) | Polyalkylene oxide-modified phospholipid and production method thereof | |
| AU2001280043B8 (en) | Derivatives of branched-chain lipophilic molecules and uses thereof | |
| JP4540287B2 (ja) | ポリアルキレンオキシド修飾リン脂質の製造方法 | |
| AU2003301763B2 (en) | Phosphate derivatives | |
| JP3857338B2 (ja) | レシチン化スーパーオキシドディスムターゼおよびそれを有効成分とする医薬 | |
| US7524981B2 (en) | Phospholipid derivatives and process for the production there | |
| AU2004252028B2 (en) | Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same | |
| US20070031481A1 (en) | Phospolipid derivative | |
| JP2714633B2 (ja) | リポソーム形成剤及びリポソーム組成物 | |
| AU2003301765B2 (en) | Phosphates of secondary alcohols | |
| JPH07188274A (ja) | 新規なガラクトース誘導体 | |
| KR20110033118A (ko) | Ｎ-아실-포스파티딜-에탄올아민의 생산 방법 | |
| HK1133658A (en) | Phosphates of secondary alcohols | |
| US20090137656A1 (en) | Intermolecular Association Complex of a Carrier and of an Active Principle | |
| Walde | Vesicle Formation from Reactive Surfactants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050928 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |